Menu

Diagnostics Group Refutes FDA’s Concerns

The Association for Molecular Pathology finds fault in the agency’s report on safety issues associated with certain lab tests.

Dec 17, 2015
Kerry Grens

PUBLIC DOMAIN IMAGES, AMANDA MILLS, USCDCPA group representing the interests of the molecular diagnostics field laid out its troubles this week (December 13) with the US Food and Drug Administration’s (FDA) concerns over laboratory developed tests. In its report, the Association for Molecular Pathology (AMP) contends that the FDA’s review of 20 tests “makes dubious claims, fails to provide significant context for the information provided, and relies on articles from the lay news media to assert its scientific positions.”

In November, the FDA had released its evaluation of the tests, which included ovarian cancer screens, Lyme disease tests, and assays to detect fetal chromosomal abnormalities.  The agency found evidence of false positives, false negatives, and “information with no proven relevance to the disease or condition for which they are intended for use.”

The FDA is planning to wield greater regulatory scrutiny over such tests. But AMP concluded “only a few of the 20 tests identified by the FDA could cause patient harms that FDA oversight might have prevented.”

GenomeWeb reported that the association “also concluded many of the 20 examples in the FDA’s report are the result of physicians using treatments outside of established medical practice or failing to follow up a screening test with more confirmatory assessments.” According to GenomeWeb, molecular diagnostics groups would prefer any additional oversight to come from an expansion of the existing framework, called the Clinical Laboratory Improvement Amendments (CLIA).

“Despite the contention from some that ‘CLIA is enough,’” the FDA said in its November report, “all of the tests described as problematic in this report were offered from laboratories following the minimum requirements of CLIA.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.